Reuters logo
BRIEF-Innocoll announces regulatory path forward
March 29, 2017 / 1:39 PM / 6 months ago

BRIEF-Innocoll announces regulatory path forward

March 29 (Reuters) - Innocoll Holdings Plc:

* Innocoll announces regulatory path forward after receiving formal FDA type a meeting minutes regarding its xaracoll (bupivacaine HCL collagen-matrix implant) new drug application

* Innocoll Holdings - announced receipt of formal type a meeting minutes from FDA relating to its new drug application (NDA) for xaracoll

* Innocoll Holdings-believes, if adequately financed, successful, additional studies may be completed in time for a NDA resubmission for xaracoll at end of 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below